CD34 and familial hyperaldosteronism: In line with this hypothesis, in our study, we found that six-month PCSK9-I therapy significantly increased the number of circulating CD34+ cells in FH subjects with a low CD34+ cell count, and it reduced the circulating CD34+ cell number in FH subjects with a higher CD34+ cell level; moreover, in both FH groups, the obtained CD34+ cell numbers were similar to those of the controls.